TOKYO--(BUSINESS WIRE)--Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc.
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
DeFloria Advancing Charlotte's Web Legacy as Pioneer in Cannabinoid Health, with Phase 2 Clinical Trials for Autism Botanical Drug Born from the founders of Charlotte's Web - the market leading brand ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...
PARAMUS, N.J., July 1, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), headquartered in Kyoto, Japan, has ...
Pharmaceutical manufacturing steps are often isolated in space and time. The synthesis, isolation and purification of the drug substance (DS) and the formulation of the drug product (DP) may be ...
The Wegovy pill's approval signifies a shift from injectable to oral dosage forms, driven by patient preference for convenience and requiring advanced formulation techniques. Rapid scaling of ...
SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) and Royalty Pharma plc (RPRX) today announced they have entered into a strategic funding ...
(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...
Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback